Despite an ever-increasing abundance of weight management programs and products attempting to reduce obesity, substantial, and long-term weight loss has not been achieved, with the exception of pharmacotherapy including glucagon-like peptide-1 (GLP-1) analogs (4, 5) or more drastic measures such as surgery among the extremely obese in general or those with associated comorbidities such as diabetes (6). This evidence concerns the gene GCG and obesity disorder.